GLPwatch
Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
J Law Med Ethics · 2024
Last updated 2026-05-28Glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, are effective for treating obesity. However, their high cost could strain the healthcare system. To make these medications accessible to Medicare beneficiaries, drug manufacturers would need to reduce their prices.
AI summary of the abstract below.
| Journal | J Law Med Ethics, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.36 |
| NIH percentile | 22 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
Glucagon-like peptide-1 receptor agonists are effective for treating obesity, but the high cost of these medications endangers the financial viability of our health care system. To ensure that these drugs are available to Medicare beneficiaries, pharmaceutical manufacturers must lower their prices.
Verbatim abstract via PubMed 38818585 ↗